Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634310 | 0.83 | ESR2 (0.42) | ESR2HDAC4TRPV4KCNH2PSEN1 | |
| SCHEMBL17633657 | 0.81 | ESR2 (0.43) | ESR2ADRA2APNMTHDAC8 | |
| SCHEMBL31707949 | 0.74 | PKM (0.47) | — | |
| SCHEMBL20757589 | 0.70 | TRPV4 (0.46) | HDAC4TRPV4SLC6A3KCNH2TAAR1 | |
| SCHEMBL31484342 | 0.70 | TRPV4 (0.46) | HDAC4TRPV4SLC6A3KCNH2TAAR1 | |
| SCHEMBL2343488 | 0.69 | ESR2 (0.40) | ESR2SLC6A3 | |
| SCHEMBL25920490 | 0.65 | HRH3 (0.47) | HDAC4TRPV4 | |
| SCHEMBL17634248 | 0.65 | PARP1 (0.45) | HDAC4TRPV4SLC6A3KCNH2TAAR1 | |
| SCHEMBL25145866 | 0.65 | HTR2C (0.57) | TRPV4KCNH2 | |
| SCHEMBL15650246 | 0.65 | HTR2A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197900-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-02-12 | — | — | EP | disclosed |
| US-9969752-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-17 | — | — | US | disclosed |
| EP-3197900-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016045127-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049099-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233412-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | ESR2 170/4885ADRA2A 2207/4885PNMT 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.